Outpace Bio
Outpace Bio, Inc. is a biotechnology company pioneering AI-powered protein design to create novel biological functions that enhance cell therapies for solid tumors. Their platform technologies, including OUTSPACER™, OUTSMART™, OUTLAST™, OUTSAFE™, and CO-LOCKR™, improve the potency, specificity, safety, and persistence of engineered T cell therapies. Founded by leaders from the Institute for Protein Design and Fred Hutch Cancer Center, Outpace Bio focuses on overcoming biological barriers to cure solid tumors, which represent over 90% of cancers. The company develops proprietary cell therapy products and collaborates with biopharma and academic partners to integrate their technologies into diverse cell therapy pipelines. With a strong scientific team and strategic collaborations, Outpace Bio is positioned to advance curative cell therapies into clinical development, addressing critical unmet needs in oncology.
Outpace Bio
Outpace Bio, Inc. is a biotechnology company pioneering AI-powered protein design to create novel biological functions that enhance cell therapies for solid tumors. Their platform technologies, including OUTSPACER™, OUTSMART™, OUTLAST™, OUTSAFE™, and CO-LOCKR™, improve the potency, specificity, safety, and persistence of engineered T cell therapies. Founded by leaders from the Institute for Protein Design and Fred Hutch Cancer Center, Outpace Bio focuses on overcoming biological barriers to cure solid tumors, which represent over 90% of cancers. The company develops proprietary cell therapy products and collaborates with biopharma and academic partners to integrate their technologies into diverse cell therapy pipelines. With a strong scientific team and strategic collaborations, Outpace Bio is positioned to advance curative cell therapies into clinical development, addressing critical unmet needs in oncology.